Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose

Glioma is the most common primary malignant brain tumor in adults with very poor prognosis. The limited new therapeutic strategies for glioma patients can be partially attributed to the complex tumor microenvironment. However, knowledge about the glioma immune microenvironment and the associated regulatory mechanisms is still lacking. In this study, we found that, different immune subtypes have a significant impact on patient survival. Glioma patients with a high immune response subtype had a shorter survival compared with patients with a low immune response subtype. Moreover, the number of B cell, T cell, NK cell, and in particular, the macrophage in the immune microenvironment of patients with a high immune response subtype were significantly enhanced. In addition, 132 genes were found to be related to glioma immunity. The functional analysis and verification of seven core genes showed that their expression levels were significantly correlated with the prognosis of glioma patients, and the results were consistent at tissue levels. These findings indicated that the glioma immune microenvironment was significantly correlated with the prognosis of glioma patients and multiple genes were involved in regulating the progression of glioma. The identified genes could be used to stratify glioma patients based on immune subgroup analysis, which may guide their clinical treatment regimen.

Automated summary

This study found that different immune subtypes have a significant impact on the survival of glioma patients. Patients with a high immune response subtype had a shorter survival, and the immune microenvironment of these patients showed enhanced immune cell infiltration. Furthermore, 132 genes related to glioma immunity were identified, and the expression levels of seven core genes were significantly correlated with the prognosis of glioma patients. These findings could be used to stratify glioma patients based on immune subgroup analysis and guide clinical treatment regimens.